Angiotensin II receptor blockers in dermatology: a narrative review

Abstract

Angiotensin II receptor blockers (ARBs) are commonly used for cardiovascular diseases, especially for patients who can’t tolerate the side effects of cough and angioedema caused by angiotensin converting enzyme inhibitors (ACEIs). However, the evidence of using ARBs in dermatology is mostly anecdotal and limited to case reports or small case series. Here we present a narrative review focusing on the therapeutic use of ARBs in dermatology and adverse cutaneous reactions due to the administration of ARBs.

Keywords:

• Angiotensin receptor blockers
• dermatology
• treatment
• cutaneous reaction
• adverse drug reaction

Disclosure statement

There is no conflict of interest in our study. Dr. Tsen‐Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for AbbVie, Boehringer Ingelheim, Celgene, EliLilly, Galderma, GSK‐Stiefel, Janssen‐Cilag, Leo‐Pharma, Merck, Novartis, Pfizer and Serono International SA (now Merck Serono International). Dr. Yang Lo has received speaking fees from AbbVie and Novartis.